Orelabrutinib, a BTK inhibitor, has received its initial NDA approval for treating autoimmune conditions in China. This marks the first acceptance for such use. Notably, no BTK inhibitors have been given the green light in China specifically for treating ITP, highlighting the significance of this milestone in healthcare advancements for the region.